China's Zhongzhi Pharmaceutical H1 revenue falls 10%

Zhongzhi Pharmaceutical Holdings

26/08/2026 12:36

Overview
China pharmaceutical maker's half-year revenue fell 10.3% yr/yr
Profit attributable to owners rose 3.8% yr/yr
Gross profit and margin declined, board recommended no interim dividend

Outlook
Company did not provide specific financial guidance or outlook for the current quarter or full year in the press release

Result Drivers
DEMAND PRESSURE – Pharmaceutical-manufacturing revenue fell 12.2% yr/yr as divergent demand, consumption contraction and channel inventory reductions weighed on sales
PHARMACY FOOTFALL DECLINE – Chain-pharmacy revenue fell 6.0% as retail competition and community hospitals' medical-insurance services diverted customer traffic

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 790 mln
 
H1 Net Income Attributable
 
RMB 9.1 mln
 

Reuters Recommended Reads
Aug 26 - China's Consun Pharmaceutical H1 revenue rises on sales network expansion
Aug 26 - Hansoh Pharma reports 36% rise in first-half profit helped by innovative drug sales
Aug 26 - Sihuan Pharmaceutical H1 profit jumps on medical aesthetics unit strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)